Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

- PMLiVE

NICE wants more data on Boehringer’s Jardiance

Pharma company needs to demonstrate cost-effectiveness of its diabetes drug

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

NICE backs Celgene’s Revlimid in bone marrow disorder

Recommends that drug can be used on NHS to treat myelodysplastic syndromes

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

National Institute for Health and Care Excellence NICE logo

Public advises NICE on value of care

Citizens Council publishes report on the way health and social care resources are allocated in the UK

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

National Institute for Health and Care Excellence NICE logo

NICE confirms wider statin use

Reduces threshold for risk of heart disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links